Healx Logo

Healx Blog - Page 2 of 10 - Healx

Healx Blog

Webinar | How to Develop In Vivo Models for Rare Disease Research

This webinar is suitable for patient groups at the beginning of their journey to create in vivo models to accelerate the research and development of novel treatments for their rare disease of interest. During this 60-minute session our speakers discuss how to successfully create and validate animal models for preclinical drug testing – from both … Continued

Meri Williams joins Healx as Chief Technology Officer

Cambridge, UK – 17 June, 2020. Healx, the AI-powered, patient-inspired technology company accelerating the discovery and development of rare disease treatments at scale, is proud to announce that Meri Williams has joined its senior leadership team as Chief Technology Officer.  Meri joins from challenger bank Monzo, where she helped scale the engineering and data team … Continued

Healx partners with Children’s Tumor Foundation to progress neurofibromatosis treatments; recruits patient advocate to lead collaborative drug discovery efforts

Cambridge UK – 15 April 2020 – Healx, the AI-powered and patient-inspired tech company specialising in accelerating the discovery and development of rare disease treatments, today announced a partnership with US and Europe-based patient group Children’s Tumor Foundation (CTF) to progress new AI-derived therapies for neurofibromatosis (NF). NF is a rare genetic disorder that affects … Continued

Healx using artificial intelligence to find combination drug treatments for COVID-19

Cambridge, UK – 6 April 2020 – Healx, the AI-powered, patient-inspired biotech specialising in rare diseases, today announces it is using its AI platform to develop drug combinations from approved drugs to contribute towards global efforts to find treatments for COVID-19. This focus on combination therapies, where two or more drugs simultaneously target different aspects … Continued

Webinar | The Rare Treatment Accelerator: Feedback for Applicants

The first call for applications to the Rare Treatment Accelerator saw an extremely high volume of interest and quality of applications received. Following the review of applications by Healx’s selection panel, an initial three patient groups and their diseases were selected to progress to the next stage of the programme. For those patient groups who … Continued